Regeneron Pharmaceuticals, Inc. REGN

788.04 (7.98) (1.00%) as of 25 Sep
Market cap
$81.3B
P/E
18.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Regeneron Pharmaceuticals, Inc. (REGN) P/S ratio

As of 25 September 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/S ratio of 5.2×. Over the past ten years it has ranged from 3.5× (June 2022) to 18.0× (June 2015); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 11.5× and above the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 5.6× 4.01%
FY2024 5.4× (26.48%)
FY2023 7.4× 16.13%
FY2022 6.3× 52.62%
FY2021 4.2× (32.11%)
FY2020 6.1× (2.16%)
FY2019 6.3× (20.17%)
FY2018 7.8× 13.08%
FY2017 6.9× (15.32%)
FY2016 8.2× (40.01%)

Quarterly

Period P/S ratio Change
Jun 2026 4.1× (23.39%)
Mar 2026 5.4× (4.32%)
Dec 2025 5.6× 37.68%
Sep 2025 4.1× 5.32%
42 more quarters

Against its own ten years

Low 3.5× High 18.0×
Ten-year median 6.7×
Current reading's percentile 19

P/S ratio against peers

Company P/S ratio
REGN Regeneron Pharmaceuticals, Inc. 5.2×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.6×
ALNY Alnylam Pharmaceuticals, Inc. compare 7.1×
RPRX Royalty Pharma PLC compare 10.2×
VRTX Vertex Pharmaceuticals Incorporated compare 10.6×
ARGX argenex SE compare 11.2×
INSM Insmed, Inc. compare 22.5×
MRNA Moderna, Inc. compare 35.5×
RVMD Revolution Medicines, Inc. compare 1,606×
Biotechnology industry median 11.5×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on REGN